TransMedics Group (NASDAQ:TMDX) Stock Price Down 3.8% – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price fell 3.8% during mid-day trading on Thursday . The stock traded as low as $61.37 and last traded at $61.50. 93,896 shares traded hands during trading, a decline of 91% from the average session volume of 1,048,580 shares. The stock had previously closed at $63.90.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Canaccord Genuity Group lowered their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Finally, Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Down 2.5 %

The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $2.05 billion, a P/E ratio of 64.92 and a beta of 2.06. The firm’s 50 day moving average price is $81.71 and its two-hundred day moving average price is $126.25.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. Equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,180,642.53. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,417 shares of company stock worth $2,240,738. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently bought and sold shares of the business. Driehaus Capital Management LLC boosted its stake in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after acquiring an additional 202,867 shares during the period. Principal Financial Group Inc. lifted its holdings in TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Hood River Capital Management LLC bought a new position in TransMedics Group during the second quarter worth $18,854,000. Canada Pension Plan Investment Board acquired a new position in shares of TransMedics Group in the second quarter valued at $16,086,000. Finally, Public Sector Pension Investment Board bought a new position in shares of TransMedics Group in the third quarter valued at about $11,079,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.